HIVAX is under clinical development by GeneCure Biotechnologies and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase II drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HIVAX’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HIVAX overview

HIVAX (replication-defective HIV-1 vaccine) is under development for the treatment of HIV-1 infections. The drug candidate is administered through subcutaneous route. It is developed based on lentiviral-based gene transfer technology.

GeneCure Biotechnologies overview

GeneCure Biotechnologies (GeneCure), formerly GeneCure is a biotechnology company that focuses on the development of gene based technology to treat genetic and acquired human diseases. The company offers products such as Hivax and SimVec. Its Hivax is a patented replication-defective HIV-1 vaccine which stimulates cellular and antibody immune responses in mouse and primate models. GeneCure also develops patented gene transfer technology SimVec based on a primate lentivirus which delivers genes into primary human cells without causing harm to humans. The company also uses its novel gene transfer technology to develop treatments for life-threatening human diseases including genetic diseases, infectious diseases, and cancers. It provides contract manufacturing services. GeneCure is headquartered in Norcross, Georgia, the US.

For a complete picture of HIVAX’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.